Central Nervous System Complications Among Oncology Patients.

Sebastian F Winter, Jasmin Jo, David Schiff, Jorg Dietrich

Journal: Hematology/oncology clinics of North America 2022;36(1):217-236

PMID: 34607715

Full Text on Elsevier Science View on PubMed

Abstract

Cancer treatment related injury to the central nervous system (CNS) is well-recognized in the setting of brain-directed radiation therapies and conventional and novel systemic anticancer therapies. Late-delayed treatment-induced CNS complications frequently result in permanent neurologic disability. Therapeutic options are supportive with limited clinical benefit, whereby alteration or discontinuation of the overall antineoplastic treatment plan is frequently necessary to prevent further neurologic injury. Better identification of patients at high risk for developing late CNS toxicities, neuroprotective strategies with modification of existing antineoplastic treatment regimens, and research efforts directed at earlier recognition and improved treatment of central neurologic complications are paramount.

Address: Department of Neurology and MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.; Division of Hematology and Oncology, Department of Internal Medicine, East Carolina University, 600 Moye Boulevard, Greenville, NC 27858-4353, USA.; Division of Neuro-Oncology, Department of Neurology, University of Virginia, 1240 Lee Street, Charlottesville, VA 22903, USA. Electronic address: [email protected].; Department of Neurology and MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. Electronic address: [email protected].

DOI: 10.1016/j.hoc.2021.08.005

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Central Nervous System, Central Nervous System Diseases, Humans, Immunotherapy, Medical Oncology, Neoplasms